Fundraising Fox

NYBC VenturesFull Portfolio

15 tracked investments · listed companies and verified rows first

▶︎ STRM.BIOstrm.bioin

STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells.

BiotechDeep TechMedical Devices

Co-investorsAscension VenturesBreakout LabsBreakout VenturesDelos CapitalKdT Ventures

Akadeum Life Sciencesakadeum.comin𝕏

Akadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products.

Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesAnn Arbor, US

Kalyan Handique(Executive Officer, Director)John Younger(Executive Officer, Director)James Militello(Executive Officer)

BoardJeffrey S. Williams(Director)Paul D'Amato(Director)Dan Kidle(Director)in

Co-investorsArboretum VenturesBeringeaBerkeley CatalystBlueStone Venture PartnerseLab VenturesID Ventures+5 more

Aronorabioaronorabio.comin

Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism.

BiotechDeep TechHealthtechPortland, US

Erik I. Tucker(President & Chief Executive Officer)in

AvenCellavencell.comin

AvenCell develops next-generation CAR-T cell immunotherapies for hard-to-treat cancers, using proprietary Universal Switchable CAR and allogeneic platforms with an on/off mechanism combining universal effector cells and soluble Targeting Modules.

BiotechMedical Devices

Co-investorsEight Roads VenturesF-Prime Capital PartnersNovo Holdings

CatenaBiocatenabio.comin

Catena Biosciences develops therapeutics using its CysTyr conjugation platform to create Multi-Payload Conjugates (MPCs), a next-generation form of antibody-drug conjugate that delivers dual payloads.

BiotechHealthtechBerkeley, US

Co-investorsFREEFLOWLongeVC

Cellular Originscellularorigins.comin

Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.

Advanced ManufacturingBiotechRoboticsCambridge, GB

Co-investorsHighland EuropeTTP Ventures

Comprehensive Cell Solutions (CCS)nybce.orgin𝕏

New York Blood Center provides blood products and clinical services, operates a genomics and cell solutions laboratory, runs a specialty pharmacy serving hemophilia treatment centers, and conducts biomedical research.

BiotechHealthtechMedical DevicesNew York, US

Functional Fluidicsfunctionalfluidics.comin𝕏Apr 2019

Functional Fluidics is a CLIA-certified diagnostic lab offering proprietary red blood cell function biomarker assays, starting with Sickle Cell Disease.

BiotechDigital HealthHealthtechMedical DevicesDetroit, US

Patrick Hines(CEO & Founder)Dr. Hines(Founder)John Cunningham(Chief Operating Officer)

Co-investorsID VenturesMichigan RiseSeae VenturesWavemaker Three-Sixty Health

Healthquestcapitalhealthquestcapital.com

HealthQuest Capital is a healthcare investment firm that funds and supports companies across medtech, digital health, and life sciences.

Digital HealthHealthtechMedical Devices

Co-investorsUnion Grove Venture Partners

Immusoftimmusoft.com

Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.

BiotechDeep TechHealthtechSeattle, US

Matthew Scholz(Founder)Sean Ainsworth(Chief Executive Officer)Robert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)Scott McIvor(Chief Development Officer)Richard Chin, M.D.(Director)

Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+1 more

KaloCytekalocyte.cominApr 2018

KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.

BiotechDeep TechHealthtechMedical DevicesBaltimore, US

Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)

Co-investorsBioAdvanceBioGenerator VenturesMaryland TEDCOOld Line Capital PartnersTEDCO

Thymmunethymmune.comin

Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease.

AI & Machine LearningBiotechLongevityCambridge, US

Stan Wang(MD, PhD)inBing Lim(MD, PhD)inManish Jain

Co-investorsPillar VC

Vega Therapeuticsvega-therapeutics.com
Vitestrovitestro.comin

Vitestro develops Aletta®, an autonomous blood collection (phlebotomy) device that uses automation and clinical validation to standardize blood draws.

HealthtechMedical DevicesRobotics

Co-investorsSonder Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.